Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 752 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Patient Guide in Testicular Cancer Now Available Also in Italian November 25, 2025 Second Interim Analysis Shows OS Improvement with Adjuvant Olaparib for Germline... October 12, 2022 Preparing for your COVID-19 Vaccine: What to Ask your Provider February 1, 2021 Biomarker Analyses in Patients with HER2-positive or HER2-low Gastric and Gastro-oesophageal... May 21, 2024 Load more HOT NEWS AI Model Identifies How Every Country Can Improve Its Cancer Outcomes FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma Hyperfractionated Intensity-Modulated Radiotherapy Decreases the Rate of Severe Late Complications and... FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer
